Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

16 evidence topics · 8 sources

Steady-state pharmacokinetic parameters at 60, 90, and 120 mg
Dose, once dailyTmax,ss, h, median [min–max]Cmin,ss, ng/mL, GeoMean (GeoCV%)Cmax,ss, ng/mL, GeoMean (GeoCV%)Cavg,ss, ng/mL, GeoMean (GeoCV%)AUC0–24,ss, ng*h/mL, GeoMean (GeoCV%)Accumulation ratio, Cmax,ssAccumulation ratio, AUC0–24,ss
60 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“116 (50.3)”View highlighted excerpt for this quote“241 (47.1)”View highlighted excerpt for this quote“168 (45.2)”View highlighted excerpt for this quote“4030”View highlighted excerpt for this quote“2.25 (57.5)”View highlighted excerpt for this quote“2.94 (51.0)”View highlighted excerpt for this quote
90 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“213 (92.7)”View highlighted excerpt for this quote“460 (77.4)”View highlighted excerpt for this quote“322 (82.1)”View highlighted excerpt for this quote“7720”View highlighted excerpt for this quote“3.55 (34.7)”View highlighted excerpt for this quote“5.12 (41.3)”View highlighted excerpt for this quote
120 mg“4.0”View highlighted excerpt for this quote“[1.00–6.00]”View highlighted excerpt for this quote“276 (41.6)”View highlighted excerpt for this quote“541 (37.4)”View highlighted excerpt for this quote“384 (37.9)”View highlighted excerpt for this quote“9210”View highlighted excerpt for this quote“1.96 (19.6)”View highlighted excerpt for this quote“4.76 (43.1)”View highlighted excerpt for this quote
Posted steady-state AUC by dose in the registry results
Dose, once dailyParticipants analyzedAUC0–24 at steady state, ng/mL*h, geometric meanGeometric coefficient of variation
30 mg“5”“1956”“33.0”
60 mg“26”“4014”“46.2”
90 mg“6”“7668”“82.4”
120 mg“77”“9163”“38.1”
150 mg“2”“12580”“27.3”
210 mg“6”“22439”“47.2”
300 mg“6”“25438”“40.2”
Effective half-life by dose during dose escalation
Dose, once dailyt1/2eff, h, GeoMeanGeoCV%
30 mg“54.7”“(26.0)”
60 mg“63.4”“(29.2)”
90 mg“72.7”“(54.1)”
120 mg“68.8”“(54.7)”
150 mg“61.6”“(23.6)”
210 mg“57.3”“(109.9)”
300 mg“51.0”“(61.7)”